IRIS
RUSCITTI, PIERO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.006
AS - Asia 5.810
EU - Europa 5.329
SA - Sud America 793
Continente sconosciuto - Info sul continente non disponibili 360
AF - Africa 106
OC - Oceania 11
Totale 23.415
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.775
SG - Singapore 2.686
RU - Federazione Russa 1.462
IE - Irlanda 1.395
CN - Cina 1.108
BR - Brasile 680
HK - Hong Kong 631
VN - Vietnam 555
IT - Italia 543
DE - Germania 395
SE - Svezia 360
TR - Turchia 328
GB - Regno Unito 232
UA - Ucraina 228
FR - Francia 201
FI - Finlandia 160
CA - Canada 123
BD - Bangladesh 115
NL - Olanda 114
IN - India 106
JP - Giappone 73
MX - Messico 55
BE - Belgio 46
AR - Argentina 43
ZA - Sudafrica 43
PL - Polonia 34
ES - Italia 32
LT - Lituania 27
ID - Indonesia 26
CZ - Repubblica Ceca 23
IQ - Iraq 22
EC - Ecuador 19
KR - Corea 16
PK - Pakistan 16
VE - Venezuela 15
AT - Austria 14
CO - Colombia 12
SA - Arabia Saudita 12
JO - Giordania 11
MA - Marocco 11
AE - Emirati Arabi Uniti 10
GR - Grecia 10
JM - Giamaica 10
TN - Tunisia 10
EU - Europa 9
IL - Israele 9
MY - Malesia 9
PH - Filippine 9
AZ - Azerbaigian 8
CH - Svizzera 8
DZ - Algeria 8
EG - Egitto 8
RO - Romania 8
UZ - Uzbekistan 8
CR - Costa Rica 7
GT - Guatemala 7
KE - Kenya 7
LB - Libano 7
NI - Nicaragua 7
NP - Nepal 7
PY - Paraguay 7
AL - Albania 6
AU - Australia 6
HN - Honduras 6
KZ - Kazakistan 6
CL - Cile 5
KW - Kuwait 5
BO - Bolivia 4
DO - Repubblica Dominicana 4
HR - Croazia 4
LU - Lussemburgo 4
MK - Macedonia 4
PE - Perù 4
SN - Senegal 4
UY - Uruguay 4
CI - Costa d'Avorio 3
DK - Danimarca 3
MM - Myanmar 3
NZ - Nuova Zelanda 3
OM - Oman 3
PT - Portogallo 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
BB - Barbados 2
BG - Bulgaria 2
CW - ???statistics.table.value.countryCode.CW??? 2
EE - Estonia 2
ET - Etiopia 2
GH - Ghana 2
HU - Ungheria 2
IR - Iran 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
MO - Macao, regione amministrativa speciale della Cina 2
PA - Panama 2
PR - Porto Rico 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
Totale 23.044
Salva come PNG Salva come JPEG
Città #
Dublin 1.392
Singapore 1.361
San Jose 1.268
Dallas 1.215
Chandler 1.137
Jacksonville 942
Ashburn 875
Hong Kong 623
Santa Clara 596
Boardman 388
Council Bluffs 376
New York 327
The Dalles 317
Moscow 262
Beijing 209
Izmir 208
Los Angeles 200
Ho Chi Minh City 172
Lawrence 161
Princeton 161
Ann Arbor 151
Hanoi 125
Nanjing 125
Wilmington 124
Lauterbourg 100
L'aquila 99
Amsterdam 96
San Mateo 83
São Paulo 83
Hefei 79
Munich 79
Milan 67
Tokyo 66
Columbus 65
Dearborn 63
L’Aquila 62
Woodbridge 57
Helsinki 52
Orem 52
Nanchang 50
Lappeenranta 47
Shanghai 45
Phoenix 44
Brussels 41
Seattle 41
Frankfurt am Main 38
Montreal 38
Houston 36
Brooklyn 33
Assago 32
Chicago 32
Des Moines 32
Rome 32
Stockholm 31
Da Nang 30
Dong Ket 30
Johannesburg 30
Mountain View 30
Shenyang 30
Kunming 29
Warsaw 28
Manchester 26
Atlanta 25
Haiphong 25
Mexico City 25
Toronto 25
Hebei 24
London 24
Denver 23
Pescara 23
San Francisco 23
Chennai 22
Tianjin 22
Jinan 21
Rio de Janeiro 21
Brno 20
Buffalo 20
Verona 20
Guangzhou 19
Jiaxing 19
Kitzingen 19
Mumbai 19
New Delhi 19
Philadelphia 19
Ankara 18
Charlotte 18
Cedar Knolls 17
Changsha 17
Falkenstein 17
Jakarta 17
Pune 17
Zhengzhou 17
Boston 15
Poplar 14
Turku 14
Belo Horizonte 13
Hangzhou 13
Porto Alegre 13
Washington 13
Brasília 12
Totale 15.345
Salva come PNG Salva come JPEG
Nome #
Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis 183
Unenhanced Cardiac Magnetic Resonance may improve detection and prognostication of an occult heart involvement in asymptomatic patients with systemic sclerosis 176
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 163
FRI0613 H-ferritin and pro-inflammatory cytokines are increased in the bone marrow of adult patients affected by macrophage activation syndrome 161
Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts 158
Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis 158
H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome 156
IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? 155
Role of CD248 molecule as potential regulator of trans-differentiation toward myofibroblasts of perivascular stromal cells in systemic sclerosis patients 155
Evaluating the multivisceral involvement on adult-onset Still’s disease to retrieve imaging-based differences in patients with and without macrophage activation syndrome: results from a single-centre observational study 155
Prognostic factors of adult onset Still’s disease: analysis of 100 cases in 3 tertiary referral centers 153
The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes 151
The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. 149
Interleukin-9 Overexpression and Th9 Polarization Characterize the Inflamed Gut, the Synovial Tissue, and the Peripheral Blood of Patients With Psoriatic Arthritis 145
The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: Correlation with disease severity and implication for pathogenesis 144
Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations 143
Cardiovascular disease in primary sjögren’s syndrome 141
Still's disease continuum from childhood to elderly: data from the international AIDA Network Still's disease registry 140
association of pathogenic and regulatory B-cell subsets with clinical and histological features in primary Sjogren's syndrome. 140
Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. 138
Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort 137
Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands 137
Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers 137
H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease 137
Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences 135
Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients 133
Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. 133
Stromal Cell-derived Factor 1 in Cardiac and Autoimmune Disease 132
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 132
Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis 131
Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 131
Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis 129
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study 128
Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. 128
Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6 127
Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts 127
Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension 127
Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. 126
Stem cell therapies for systemic sclerosis 125
SENESCENT BONE MARROW DERIVED MESENCHYMAL STEM CELLS (MSC) ARE PRONE TO RECOVER DURING SSC 125
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. 125
Dissecting the clinical heterogeneity of adult-onset Still's disease, results from a multi-dimensional characterisation and stratification 125
Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. 124
Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study 124
A comprehensive review on adult onset Still's disease 122
The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. 122
Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review) 121
Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies a very early cardiac involvement in systemic sclerosis patients of recent onset 120
Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling 120
Parenchymal lung disease in adult onset Still's disease: An emergent marker of disease severity - Characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients 120
Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still's disease 119
Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities 119
Diagnostic and interventional radiology fundamentals of synovial pathology 119
Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms 118
Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort 118
Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. 118
Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment 118
Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander? 117
Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry 116
EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease 116
Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. 116
Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. 116
Macrophage activation syndrome in patients affected by adult-onset still disease: Analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in reumatologia clinica e sperimentale cohort 116
Searching for a good model for systemic sclerosis: The molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis 116
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy 115
Macrophages with regulatory functions, a possible new therapeutic perspective in autoimmune diseases 115
Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis 114
Long-term Safety of Rituximab in Primary Sjögren Syndrome: The Experience of a Single Center 113
EFFICACY AND SAFETY OF RITUXIMAB TREATMENT IN EARLY PRIMARY SJOGREN'S SYNDROME: A CLINICAL, HISTOLOGICAL AND MOLECULAR STUDY 113
T helper 1 response is correlated with widespread pain, fatigue, sleeping disorders and the quality of life in patients with fibromyalgia and is modulated by hyperbaric oxygen therapy 113
Interstitial lung disease in systemic sclerosis: current and future treatment. 113
Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. 112
Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study 112
IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study 112
Nail and enthesis assessment in patients with psoriatic disease by high frequency ultrasonography: findings from a single-centre cross-sectional study 111
The assessment of atlantoaxial joint involvement in patients with rheumatoid arthritis, results from an observational "real-life" study 111
The Role of IL-1β in the Bone Loss during Rheumatic Diseases 111
Response to: ‘Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences’ by Ruscitti et al’ by Chen et al 111
Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm. 111
Is minor salivary gland biopsy more than a diagnostic tool in primary Sjo¨gren׳s syndrome? Association between clinical, histopathological, and molecular features: A retrospective study 110
Diminished expression of the ubiquitin-proteasome system in early treatment-naïve patients with rheumatoid arthritis and concomitant type 2 diabetes may be linked to IL-1 pathway hyper-activity; results from PEAC cohort 109
The Systemic Score May Identify Life‐Threatening Evolution in Still Disease: Data from the GIRRCS AOSD‐Study Group and the AIDA Network Still Disease Registry 109
Computed Tomography and MR Imaging in Rheumatoid Arthritis 109
Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. 109
Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: Results from a cross-sectional study. 108
The Vessels Contribute to Fibrosis in Systemic Sclerosis 108
CARDIAC MAGNETIC RESONANCE IMAGING WITH PHARMACOLOGICAL STRESS PERFUSION IN ASYMPTOMATIC PATIENTS WITH SYSTEMIC SCLEROSIS 108
Myofibroblast Cells Expression of CD248 May Contribute to Exacerbate Microvascular Damage during Systemic Sclerosis 108
The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile 108
Il Laboratorio nelle malattie autoimmuni sistemiche 107
Glucocorticoids in Rheumatoid Arthritis: The Silent Companion in the Therapeutic Strategy 107
Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial 107
ASSESSING PRO-INFLAMMATORY PROPERTIES OF H-FERRITIN BY EX VIVO AND IN VITRO OBSERVATIONS 107
Unfolding dermatologic spectrum of Behçet’s disease in Italy: real-life data from the International AIDA Network Behçet’s disease Registry 106
Laboratory assessment in patients with suspected rheumatic musculoskeletal diseases: challenges, pitfalls and perspectives 106
Decreased Expression of Angiopoetin 1 on Perivascular Mesenchymal Stem Cells from Ssc Patients Induces an Anti Angiogenetic Effect, when Co-cultured with Endothelial Cells 104
The administration of methotrexate in patients with Still's disease, “real-life” findings from AIDA Network Still Disease Registry 103
SAT0489 Biologic Therapies and Infections in The Daily Practice: A Study on Historical Cohort from 3 Italian Rheumatologic Units 103
Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI). 103
The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study 102
Totale 12.474
Salva come PNG Salva come JPEG
Categoria #
all - tutte 111.216
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 111.216
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022764 0 24 153 63 17 12 31 42 66 44 61 251
2022/20233.501 226 193 60 362 209 328 49 217 1.676 21 119 41
2023/20241.043 117 46 69 99 76 325 31 54 22 59 41 104
2024/20254.770 118 79 404 213 624 449 575 308 1.120 222 344 314
2025/20269.242 507 918 823 992 887 562 1.572 368 894 1.023 549 147
2026/2027637 314 323 0 0 0 0 0 0 0 0 0 0
Totale 23.415